MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation ROCE Ratio 2011-2026 | AGTC
Annual ROCE Ratio Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -60.13 | -21.49 | -21.28 | -5.25 | -21.49 | 1.59 | -1.66 | -28.68 | -16.77 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.59 | -60.13 | -19.46 |
Quarterly ROCE Ratio Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -156.06 | -191.87 | -88.33 | -156.04 | -148.0 | -148.58 | -161.23 | -129.92 | -135.88 | -114.35 | -98.05 | -76.52 | -67.36 | -58.63 | -37.67 | -28.94 | -10.34 | -9.79 | -12.23 | -11.67 | -14.08 | -6.47 | -1.85 | 5.71 | 10.26 | 11.05 | -1.58 | -0.19 | -14.06 | -21.67 | -17.51 | -27.15 | -23.6 | -13.38 | -2.64 | 7.2 | 8.99 | 8.99 | 3.56 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.05 | -191.87 | -49.48 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 7.71 | 1.65 % | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
-42.02 | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 221.52 | -0.16 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Heron Therapeutics
HRTX
|
-17.71 | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-119.71 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Immunovant
IMVT
|
-70.24 | $ 24.27 | 5.61 % | $ 3.68 B | USA |
 |
Incyte Corporation
INCY
|
29.32 | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
-79.65 | $ 1.23 | 5.13 % | $ 22.1 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-122.66 | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Innate Pharma S.A.
IPHA
|
0.41 | $ 1.34 | 14.26 % | $ 235 M | France |
 |
Calithera Biosciences
CALA
|
-1377.15 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
80.97 | - | -7.23 % | $ 13 M | USA |
 |
Inventiva S.A.
IVA
|
-23.77 | $ 6.09 | 5.36 % | $ 138 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
-91.44 | $ 16.93 | -0.41 % | $ 841 M | Britain |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
37.04 | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.33 | 0.97 % | $ 260 M | Israel |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |